Researchers are making efforts in designing liquid biopsies for brain tumors by spotting tumor DNA in the liquid from around the spine and brain.
Liquid biopsies are patients’ fluid samples, for instance from the urine or blood, which offer a less invasive method to observe disease in comparison to tumor biopsies. A less intrusive trial might be hugely advantageous for brain tumors where gathering samples can be risky and difficult for patients.
Researchers at the Cancer Research UK Cambridge Institute analyzed CSF (cerebrospinal fluid)—which bathes the spinal cord and brain—in 13 people suffering from a type of brain tumor subbed as glioma. They detected tumor DNA in 39% (five) of the people and their results are posted in EMBO Molecular Medicine.
Scientists employed a widely available and cheap method dubbed as shallow whole-genome sequencing to locate the DNA of brain tumor. They sought for huge genetic modifications, such as genes being lost or duplicated.
Speaking of liquid biopsy, researchers have developed an extremely responsive blood test with an ability to detect small traces of cancer-specific DNA. This test can precisely verify whether patients with HPV-linked oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer after the completion of their radiation therapy.
The novel liquid biopsy test can measure fractions of DNA dropped by cancers cells in the blood. This test might help in saving thousands of dollars per patient by minimizing the requirement for expensive radiological tests including PET/CT scans subsequent to radiation therapy.
The results of this research are supposed to be presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Bhisham Chera, Associate Professor at University of North Carolina for Radiation Oncology, proclaimed that their research team has created an extremely precise and responsive liquid biopsy blood test.